Pirouette Pharma Analysis: $6M Raised
What is Pirouette Pharma?
Pirouette Pharma develops OnePush, a disc-shaped auto-injector with a fully automatic hidden needle and controlled insertion. The company positions the platform as API-agnostic and partner-ready for co-development with pharmaceutical companies. It also references FDA 505(b)(2) and 351(k) pathways for improved injectable medicine presentations.
Location
200 International Dr, Portsmouth, New Hampshire, 03801, US
Employees
11-50
Founded
2017
Investors
- Safar Partners
- Y Combinator
Product Features & Capabilities
- Emergency auto-injector for severe allergic reactions, potential for opioid overdose treatment, advanced drug delivery systems.
How much Pirouette Pharma raised
Community Round (not specified) - $6,049,106
Closing on March 13, 2024Lead Investor: 3,898 investors, backed by Y Combinator, Safar Partners, Liquid 2 Ventures, Gaingels
Who are the founders of Pirouette Pharma
Market Focus
Pirouette Pharma primarily focuses on the healthcare industry, specifically in developing innovative healthcare solutions, including advanced drug delivery systems and therapies aimed at enhancing patient care and improving lives.
Competitors Overview
Pirouette Pharma operates in the pharmaceutical drug delivery market, which is highly competitive. Key competitors include:
-
Bayer AG: Known for its extensive research and development capabilities, Bayer focuses on innovative drug delivery systems and has a strong presence in various therapeutic areas.
-
Johnson & Johnson: This company has a diverse portfolio, including advanced drug delivery technologies and a strong emphasis on patient-centric solutions, which enhances its competitive edge.
-
Pfizer Inc.: Pfizer is recognized for its significant investments in biotechnology and drug delivery innovations, particularly in the areas of vaccines and biologics.
-
Novartis AG: Novartis has made strategic acquisitions, such as Kedalion Therapeutics, to enhance its drug delivery capabilities, particularly in ophthalmology.
-
Merck & Co., Inc.: Merck focuses on integrating nanotechnology into its drug delivery systems, providing advantages in terms of efficacy and patient compliance.
Notable differences among these competitors include their specific focus areas, technological advancements, and strategic partnerships that enhance their market positions. For instance, Novartis's focus on ophthalmic drug delivery and Merck's integration of nanotechnology are significant differentiators.
See something that needs updating? Suggest edits to this profile.